PBYIPuma Biotechnology, Inc.
$9.98+93% 1Y
$9.98
$4.7352 weeks$9.98
Latest close: a new 52-week highOct 8, 2026what changed →
The financials
Puma Biotechnology, Inc. by the numbers
Puma Biotechnology, Inc. (PBYI) reported revenue of $57M in Q2 2026 (quarter ended Jun 30, 2026), up 7.8% from the same quarter a year earlier. That came with a gross margin of 78% and net income of $8.2M (14% of revenue). For the full year FY2025, revenue was $228M (−0.9% year on year) and net income $31M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $57M | $52M | +7.8% |
| Gross profit | $44M | $40M | +9.7% |
| Operating income | $7.6M | $6.6M | +14% |
| Net income | $8.2M | $5.9M | +40% |
| Diluted EPS | $0.16 | $0.12 | +33% |